Bluebird Bio stock rises 62%, FDA committee supports treatments
June 10, 2022 at 17:40 PM EDT
Shares of Bluebird Bio Inc. rally more than 60% after news that a U.S. FDA committee supports two of the company's gene therapies.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions. |
|